glp-1 and sleep apnea GLP-1/Zepbound: Changing the Landscape of Care Sleep Apnea, GLP-1 Medications &

[Ref] Renal Common (1% to 10%): Kidney failure (chronic hemodialysis patients) [Ref] Endocrine Common (1% to 10%): Parathyroid disorder [Ref] Respiratory Very common (10% or more): Pharyngitis (27%), cough increase (18%), dyspnea (11%), rhinitis (11%) Common (1% to 10%): Bronchitis, sinusitis [Ref] Dermatologic Common (1% to 10%): Pruritus, rash [Ref] Ocular Common (1% to 10%): Amblyopia, eye disorder [Ref] Genitourinary Common (1% to 10%): Urinary tract infection [Ref] Cardiovascular Very common (10% or more): Hypertension (21%), hypotension (19%) Common (1% to 10%): Atrial fibrillation, arrhythmia, cardiovascular disorder, electrocardiogram abnormal, palpitations, tachycardia, vascular disorder [Ref] Hypersensitivity Common (1% to 10%): Allergic reaction [Ref] Psychiatric Common (1% to 10%): Depression, anxiety, drug dependence, insomnia [Ref] Immunologic Very common (10% or more): Infection (24%) [Ref] References 1

CJC-1295 with DAC is a long-acting GHRH analog conjugated to a Drug Affinity Complex studied for its roles in pituitary somatotroph signaling, growth hormone pulsatility, and IGF-1 axis modulation

Lu SC, Chen M, Atangan L, Killion EA, Komorowski R, Cheng Y, et al

For more information, please contact us today or book an appointment online now